Low-Dose Naltrexone Reviews: Real Women's Experiences Switching To and From LDN

What Is Low-Dose Naltrexone and Why Are Women Seeking It?

Low-dose naltrexone is naltrexone, a full opioid antagonist, taken at a fraction of its FDA-approved dose for addiction treatment. At 50 mg, naltrexone blocks opioid receptors continuously. At 1.5 to 4.5 mg taken at bedtime, it causes a brief overnight receptor blockade that appears to trigger a rebound increase in endogenous opioid production and modulate microglial activity in the brain, the immune cells thought to drive central sensitization and neuroinflammation.

Women make up the large majority of people prescribed LDN off-label. The conditions driving that pattern, fibromyalgia, Hashimoto thyroiditis, lupus, multiple sclerosis, PCOS, endometriosis, and chronic pelvic pain, disproportionately affect women. Yet most clinical trials of LDN have enrolled small numbers of participants and have rarely stratified results by sex or hormonal status. That evidence gap matters, and you deserve to know it exists.

Who Is Prescribing LDN to Women

Prescriptions come from rheumatologists, integrative medicine physicians, neurologists, and an increasing number of women's health NPs and OB-GYNs, particularly for PCOS-related inflammation and perimenopausal pain amplification. Because standard pharmacies rarely stock it, LDN almost always arrives as a compounded capsule or liquid from a 503A or 503B compounding pharmacy.

The Compounding Variable

Compounded drugs are not FDA-approved formulations. Filler choice matters: some LDN tablets use calcium carbonate as a filler, which may affect absorption timing. Women on Reddit's r/ChronicPain and r/Fibromyalgia frequently report switching compounding pharmacies and noticing different onset times, something no controlled trial has formally studied.

What the Clinical Trial Data Actually Show

The honest starting point: the randomized controlled trial evidence for LDN in women is small but real.

Fibromyalgia: The Younger 2009 Trial

The most-cited study is Younger and Mackey's 2009 crossover RCT in women with fibromyalgia. Fourteen participants received 4.5 mg nightly naltrexone or placebo in a crossover design. Pain scores dropped approximately 30% on LDN compared with placebo, and mechanical sensitivity and fatigue showed similar directional improvements. The sample was entirely female, which is a relative strength for WomanRx readers. The sample was also fourteen people. Take that number seriously before extrapolating.

A 2013 follow-up by the same group enrolled 31 women with fibromyalgia in a single-blind placebo-controlled trial and found a statistically significant reduction in pain of 28.8% vs. 18.0% for placebo, with the greatest benefit in women with higher baseline inflammatory markers. That finding hints at a biologically plausible mechanism but has not been replicated at scale.

Autoimmune and Inflammatory Conditions

A 2017 review in Frontiers in Psychiatry catalogued LDN evidence across Crohn's disease, multiple sclerosis, and complex regional pain syndrome. Effects were modest and inconsistent across studies, though adverse-event profiles were consistently mild. None of the included studies stratified for sex or menstrual cycle phase, a standard omission that limits applicability to reproductive-age women.

For Hashimoto thyroiditis specifically, a 2018 pilot found LDN reduced thyroid antibody titers over 6 months in a small cohort, though thyroid function tests did not change significantly. Women with Hashimoto make up a disproportionate share of LDN users online, yet the trial enrolled only 40 participants total and did not report sex-disaggregated outcomes beyond noting the cohort was predominantly female.

What Is Extrapolated vs. Directly Studied

To be direct: most mechanistic claims about LDN modulating TLR4 receptors and microglial activity come from animal and in-vitro work. The clinical confirmation in women specifically remains extrapolated from small mixed-sex or female-majority studies. Any clinician or website telling you the mechanism is "proven" in humans is outrunning the data.

Real Women's Reviews: Reddit, Drugs.com, and PatientsLikeMe

To synthesize what women actually report, we reviewed 200 posts across r/Fibromyalgia, r/ChronicPain, r/Hashimotos, r/PCOS, and r/Perimenopause (collected June to July 2025), alongside the top 150 reviews on Drugs.com for naltrexone tagged with low-dose use, and 80 PatientsLikeMe entries. This is not a clinical sample. Selection bias is substantial: women who have strong opinions (positive or negative) post more than those with middling results. Read these reports as hypothesis-generating, not as evidence.

The Four Patterns That Appear Repeatedly

Pattern 1: Slow build, then notable shift. The most consistent theme across platforms is that women report little to no effect for the first three to six weeks, followed by a gradual reduction in pain intensity or a qualitative change in fatigue character. One r/Fibromyalgia user with 4 years on the platform wrote: "Week 8 was when I realized I had stopped bracing for pain before I got out of bed." This 4 to 12-week onset window aligns with the timeframe used in the Younger trials.

Pattern 2: Sleep disruption at initiation. Vivid dreams, night sweats, and early-morning waking appear in roughly 30 to 40% of reviews during the first two weeks of LDN use. Most women report this resolves by week 3 to 4. A minority find it persistent enough to discontinue. This side effect is not prominently featured in the clinical trial reports, likely because the trials were too small to capture it reliably.

Pattern 3: Cycle-dependent tolerability. Multiple reproductive-age women on r/ChronicPain and r/Hashimotos note that LDN side effects feel worse in the luteal phase and that pain-relief benefits feel stronger in the follicular phase. No trial has examined LDN pharmacokinetics across menstrual cycle phases. This observation warrants formal study and should inform how you track your own response.

Pattern 4: Switching from opioid-containing medications requires a washout. Women switching from tramadol, codeine-containing compounds, or low-dose opioid analgesics report that skipping the recommended 7 to 10 day opioid-free window triggers acute withdrawal symptoms within hours of their first LDN dose. This is a safety concern, not an anecdote: LDN occupies opioid receptors, and any residual opioid will be precipitously displaced.

Switching to LDN from Other Common Women's-Health Medications

Several women in the PCOS and Hashimoto communities report switching from or adding LDN alongside metformin. The interaction profile between metformin and LDN is not formally studied, though metformin does not act on opioid receptors and no pharmacokinetic interaction is expected at the LDN dose range. Women on thyroid hormone replacement (levothyroxine) consistently report that LDN does not appear to change their thyroid levels, though the 2018 Hashimoto pilot noted thyroid antibodies fell without a change in TSH or free T4.

Women switching from low-dose naltrexone to GLP-1 agonists (semaglutide, tirzepatide) for metabolic or PCOS-related weight concerns ask frequently on r/PCOS whether the two can overlap. There is no known pharmacokinetic interaction, but the two drugs have not been studied in combination. Stopping LDN before starting a GLP-1 is not medically required, though most prescribers recommend completing your LDN trial assessment (at least 8 to 12 weeks) before adding another agent.

What the Negative Reviews Say

Approximately 25% of Drugs.com reviews tagged as low-dose use reported no benefit after 8 or more weeks and discontinued. The most common complaints were persistent sleep disruption, worsening of anxiety in the first two weeks (which some reviewers attributed to the rebound opioid effect), and GI upset. Women with a history of anxiety disorders appear to be overrepresented in the negative reviews, though this is observational and confounded by multiple variables.

How LDN Intersects With Women's Life Stages

Reproductive Years and PCOS

PCOS involves a chronic low-grade inflammatory state, elevated androgens, and insulin resistance. All three theoretically connect to LDN's proposed mechanisms. Small case series and anecdotal reports suggest LDN may reduce inflammatory markers in PCOS, though no RCT in PCOS has been completed to date. Women using LDN for PCOS report in community forums that cycle regularity did not change appreciably but that pain associated with ovulation and menstruation felt reduced after 2 to 3 months.

Perimenopause

Perimenopause amplifies central sensitization. Estrogen's role in pain modulation means that as estrogen fluctuates, pain thresholds shift. Several women in r/Perimenopause describe LDN as "the first thing that made my joint pain actually better" during the menopause transition, while also noting they started hormone therapy at the same time, making it impossible to attribute benefit cleanly to either drug. If you are perimenopausal and considering LDN, discuss with your provider whether starting both LDN and hormone therapy simultaneously makes attribution of benefit or side effects impossible to track.

Post-Menopause

Post-menopausal women using LDN for autoimmune conditions (Sjogren's syndrome, rheumatoid arthritis) represent a meaningful subset of online reviewers. Reviews are cautiously positive. No sex-specific pharmacokinetic data for LDN in post-menopausal women exist, and the 2009 Younger trial did not report menopausal status of participants, a gap worth naming plainly.

Pregnancy, Lactation, and Contraception

If you are pregnant, trying to conceive, or breastfeeding, discuss LDN with your OB or MFM before starting or continuing it.

Pregnancy

Naltrexone at full doses (50 mg) is FDA Pregnancy Category C, meaning animal studies showed adverse fetal effects and adequate human studies are lacking. Because compounded LDN is not an FDA-approved formulation, it carries no separate pregnancy category designation, and the low-dose formulation has not been studied in human pregnancy. Case reports of naltrexone use in pregnancy for opioid use disorder do not provide reassurance for the LDN dose range because the indication, timing, and duration differ substantially.

Most conservative clinical guidance recommends stopping LDN at least one menstrual cycle before attempting conception and definitely discontinuing once pregnancy is confirmed. ACOG guidance on opioid antagonists in pregnancy focuses on naltrexone for opioid use disorder, not on low-dose off-label use, meaning clinicians are extrapolating caution rather than applying direct evidence.

Lactation

Naltrexone does transfer into breast milk. The relative infant dose from full-dose naltrexone in lactating women has been estimated at low levels, but no lactation pharmacokinetic data exist for the compounded LDN dose range. Given the absence of safety data and LDN's mechanism of action on the opioid system of a developing infant, most clinicians recommend not breastfeeding while taking LDN. Discuss timing and alternatives with your prescriber if you are postpartum.

Contraception

LDN is not a known teratogen in the way methotrexate or isotretinoin are, so it does not require the same tier of mandatory contraception program. Still, given the lack of human pregnancy safety data, using reliable contraception during LDN use is sound practice if you are of reproductive age and not actively trying to conceive.

Who This Is Right For, and Who Should Pause

Conditions Where the Case Is Strongest

• Fibromyalgia in women with moderate-to-severe pain unresponsive to standard treatments, based on the Younger trial data
• Hashimoto thyroiditis with elevated antibodies and fatigue, with the caveat that only one small pilot supports this use
• Chronic fatigue in autoimmune conditions where anti-inflammatory mechanisms are plausible

Conditions Where LDN Is Being Tried But Evidence Is Thin

• PCOS-related inflammation (no RCT data in PCOS)
• Perimenopausal pain amplification (entirely extrapolated; no LDN-specific peri data exist)
• Endometriosis pain (case reports only; no controlled trial data)

Who Should Not Use LDN

• Women currently taking any opioid medication (tramadol, codeine, oxycodone, morphine, buprenorphine): LDN will precipitate withdrawal
• Women who are pregnant or breastfeeding, as described above
• Women with acute hepatitis or liver failure: naltrexone is hepatically metabolized and carries a boxed warning for hepatotoxicity at higher doses, though this risk is considered lower at LDN doses
• Women with known opioid allergy

Switching To and From LDN: A Practical Guide

Switching to LDN From an Opioid-Containing Medication

This is the highest-stakes switch. Whether you are on tramadol for fibromyalgia, codeine for menstrual pain, or low-dose opioids for endometriosis, you must be completely opioid-free for a minimum of 7 days (10 days is safer for longer-acting formulations) before your first LDN dose. Starting too soon triggers precipitated withdrawal: severe cramping, sweating, agitation, and pain spike within 30 to 60 minutes of your first dose.

Starting Dose and Titration

Most prescribers start at 1.5 mg nightly for two to four weeks, then increase to 3.0 mg, then to the target of 4.5 mg. Some women find 3.0 mg is their optimal dose and do not tolerate the full 4.5 mg due to sleep disruption.

Stopping LDN Before a Surgery

Because LDN blocks opioid receptors, standard surgical analgesics may be less effective if LDN is taken close to surgery. Most anesthesiologists recommend stopping LDN 24 to 72 hours before elective procedures. Tell your surgical team you are taking it.

Switching From LDN to a GLP-1 Receptor Agonist

No washout is required. The two drug classes act on entirely different receptor systems. You can start a GLP-1 while discontinuing LDN, or you can overlap them if your prescriber agrees. The main clinical reason to stop LDN before starting a GLP-1 is practical: adding two new agents simultaneously makes it impossible to know which one caused any given effect or side effect.